Document is current
Any future updates will be listed below
-
Authors
Pan, Xingxiu
Munan, Subrata
Zuckerman, Austin L.
Pon, Andrew
Thompson, Niklas B. https://orcid.org/0000-0003-2745-4945
Perera, Rasangi M. https://orcid.org/0000-0002-1394-4006
Shrestha, Nirajan https://orcid.org/0000-0003-1259-0661
Violante, Sara
Cross, Justin R.
Goodman, Russell P. https://orcid.org/0000-0003-3881-7895
Shah, Hardik https://orcid.org/0000-0001-8408-5686
Cracan, Valentin https://orcid.org/0000-0002-3280-0593
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM142495)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R03CA286706)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK134675)
- License Information
-
More Information
Article History
Received: 20 March 2025
Accepted: 19 December 2025
First Online: 16 February 2026
Competing interests
: V.C., X.P. and A.L.Z. are listed as inventors on a patent application (no. 63/812,699: ‘Enzyme-based compositions and methods for treating mitochondrial dysfunction’) based on sequences and activities of proteins described in this paper. V.C. is listed as an inventor on a patent application on the therapeutic uses of Lb NOX and TPNOX (US patent application US20190017034A1). The other authors declare no competing interests.
